Neurocrine Biosciences, Inc. (NBIX) Posts Q3 EPS of $0.56, Revenues Rose 189% Y/Y
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $167.77 -0.46%
Revenue Growth %: +27.0%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
PKE, LNN, More
Revenue Growth %: +27.0%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
PKE, LNN, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q3 EPS of $0.56, which may not compare to the analyst estimate of $0.19. Revenue for the quarter came in at $41.6 million versus the consensus estimate of $21.64 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine starts CAH drug trial in children under age 4
- Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
